Skip to Main Content Skip to Site Map Skip to Accessibility Statement
Home Service DREAM

DREAM

 

Trial Acronym DREAM
Trial Title Determining the Role of Synthetic Cannabinoids in Eye Pressure And Tolerability Measurements (DREAM)
Clinical Area Ophthalmology
Trial Status Open to Recruitment
Trial Registration ISRCTN10996483: Determining the role of synthetic cannabinoids in eye pressure and tolerability measurements

 

  • Recruitment
    Recruitment Target 10
    Date Open to Recruitment 8th July 2026
    Recruitment
    Date Closed to Recruitment
  • Trial Design
    Trial Design A pilot, randomised, double-masked, placebo-controlled, single site, cross-over trial
    Study Aim Aim

    The study aims to assess the preliminary efficacy and safety of a peripherally selective, synthetic cannabinoid (ART27.13), given orally, to reduce intraocular pressure (IOP) in patients with ocular hypertension or early primary open angle glaucoma

     

    Objectives

    1. To evaluate the IOP lowering efficacy of ART27.13
    2. To assess the safety and tolerability of ART27.13
  • Chief Investigator (CI)

     

    Chief Investigator

     

    		 Professor Augusto Azuara-Blanco, Queen’s University Belfast

    a.azuara-blanco@qub.ac.uk
  • Sponsor(s) & Funder(s)
    Sponsor Belfast Health & Social Care Trust
    Funder Glaucoma UK

    Public Health Agency (PHA), Health and Social Care (HSC) Research & Development Division, Northern Ireland

Quick Links